Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

BenzingaSep 9 14:28 ET

Fulcrum Rises After BofA Upgrades Rating on Chance of FSHD Study Success

Seeking AlphaSep 9 12:02 ET

Fulcrum Therapeutics Analyst Ratings

BenzingaSep 9 07:39 ET · Ratings

Athira Plunges as Alzheimer's Trial Setback Leads to Downgrades

Seeking AlphaSep 4 15:37 ET

Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

BenzingaSep 4 06:39 ET

Applied Therapeutics Analyst Ratings

BenzingaAug 27 10:33 ET · Ratings